tiprankstipranks

Bionomics initiates patient screening for the Phase 3 AFFIRM-1 trial

Bionomics initiates patient screening for the Phase 3 AFFIRM-1 trial

Bionomics announced the initiation of patient screening for the Phase 3 AFFIRM-1 trial evaluating the safety and efficacy of BNC210 for the acute, as-needed treatment of social anxiety disorder. Dr Papapetropoulos added, “We remain committed to advancing BNC210, a potential first- and best-in-class candidate with FDA Fast Track designation for both SAD and PTSD and look forward to sharing an update about our PTSD program following the recently completed EoPh2 meeting with the FDA.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue